9/12/2005
EU welcomes permanent WTO solution on generic medicines
The
EU welcomes the decision taken this week in the World Trade
Organisation to amend the WTO Agreement on Intellectual Property
with a view to improving access to medicines for developing countries.
The EU had called on WTO Members to adopt such measures as part
of a development package for the Hong Kong Ministerial. This
decision will allow poor countries without manufacturing capacities
in the pharmaceutical sector to import generic medicines for
humanitarian purposes. It will replace the temporary decision
adopted by WTO on 30 August 2003 to this effect. This amendment
will safeguard the balance of rights and obligations of the TRIPS
Agreement. The EU took an active part, as honest broker, in the
negotiations on the amendment.
EU Trade Commissioner Peter Mandelson said: “I
am very glad that we have been able to reach agreement on this
important
question. It is a first contribution for a Hong Kong Ministerial
development package. The EU has worked hard for this outcome
and welcomes that others have moved to make this possible.”
The EU is fully committed to implement at EU level the system
set up by the decision. Last week, the European Parliament cleared
the way for its full implementation by European Member States
before the end of the year. The EU calls on other WTO members
to implement the system as well.
Trade rules that answer the needs of the poorest
This decision shows that the WTO rules are flexible and that
the WTO can adapt its rule book to answer humanitarian concerns.
This decision is a positive signal before Hong Kong. It gives
countries in need a permanent solution to the problem of crucial
access to important medicines to treat pandemics. This is a key
part of the development package the EU has proposed for adoption
at Hong Kong.
This decision constitutes a key element in the fight against
communicable diseases, especially in poor countries. Measures
like this that make cheaper drugs available need to be combined
with stable and functioning healthcare systems and better public
awareness of disease risks through education.
A permanent solution for a pressing problem
At the launch of the Doha Development Agenda in Doha in November
2001, WTO members agreed to find a solution giving developing
countries with no manufacturing capacity the possibility to import
generic drugs from third countries. A temporary solution was
found in August 2003. It has now been converted into a permanent
solution.
This decision transposes the WTO temporary decision of 30 August
2003 into an amendment of the WTO Agreement on Trade-related
Intellectual Property Rights (TRIPS Agreement).
The amendment of the TRIPS Agreement will allow countries to
export generics to third countries with no manufacturing capacity
in the pharmaceutical sector, by making effective use of compulsory
licences. It includes safeguards against abuse and trade diversion
and rules to ensure transparency. The decision also contains
provisions on transfer of technology and regional cooperation.
WTO members will have until 1 December 2007 to ratify the amendment
in accordance with their national laws.
The decision is the final piece of the jigsaw to make the Doha
Declaration on the TRIPS Agreement and Public Health fully operational.